Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88.5Revenue $M40.0Net Margin (%)8.7Z-Score17.3
Enterprise Value $M-5.8EPS $0.4Operating Margin %-0.1F-Score3
P/E(ttm))25.5Cash Flow Per Share $0.1Pre-tax Margin (%)11.0Higher ROA y-yN
Price/Book0.810-y EBITDA Growth Rate %0Quick Ratio32.8Cash flow > EarningsN
Price/Sales2.25-y EBITDA Growth Rate %0Current Ratio37.4Lower Leverage y-yY
Price/Cash Flow57.2y-y EBITDA Growth Rate %-62.5ROA % (ttm)3.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)3.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M9.5ROI % (ttm)3.9Gross Margin Increase y-yN

Gurus Latest Trades with GENC

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GENCJohn Keeley 2010-03-31 Sold Out $6.9 - $7.8
($7.31)
$ 9.327%Sold Out0
GENCJohn Keeley 2009-09-30 Buy $6.38 - $8.35
($7.23)
$ 9.329%New holding, 30000 sh.30,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Houtkin Sherry10% Owner 2014-12-08Sell2,948$9.72-4.32view
Houtkin Sherry10% Owner 2014-12-02Sell5,000$9.93-6.34view
Houtkin Sherry10% Owner 2014-11-25Sell200,000$9.250.54view
Houtkin Sherry10% Owner 2014-09-04Sell29$10.19-8.73view
Houtkin Sherry10% Owner 2014-09-02Sell5,000$10.18-8.64view
Houtkin Sherry10% Owner 2014-08-26Sell5,346$10.23-9.09view
Houtkin Sherry10% Owner 2014-08-21Sell8,392$10.18-8.64view
LYONS JEANNE MSecretary 2014-03-14Sell265$10.9-14.68view
LYONS JEANNE MSecretary 2014-03-11Sell1,500$10.93-14.91view
LYONS JEANNE MSecretary 2014-02-20Sell2,000$10.97-15.22view

Press Releases about GENC :

    Quarterly/Annual Reports about GENC:

    News about GENC:

    Articles On GuruFocus.com
    Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
    comment on GENC Aug 24 2012 
    comment on GENC Aug 13 2012 
    comment on GENC Jul 11 2012 
    comment on GENC Jul 11 2012 
    comment on GENC Jul 11 2012 
    Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
    “Assign Yourself the Right Story” Mar 05 2012 
    comment on GENC Mar 05 2012 
    Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 

    More From Other Websites
    Report Pursuant to Section 28a of the Danish Securities Trading Act Dec 15 2014
    Grant of Restricted Stock Units to Board Members and Management and Grant of Warrants to Management... Dec 15 2014
    GENCOR INDUSTRIES INC Financials Dec 13 2014
    Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen Dec 12 2014
    10-K for Gencor Industries, Inc. Dec 11 2014
    GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 09 2014
    GENCOR INDUSTRIES INC Files SEC form 10-K, Annual Report Dec 09 2014
    Gencor Releases Fiscal Year and Fourth Quarter 2014 Results Dec 09 2014
    Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas Dec 04 2014
    Genmab to Webcast Post-ASH Investor Seminar Dec 03 2014
    Genmab's Total Number of Voting Rights and Total Share Capital Nov 28 2014
    Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma Nov 24 2014
    Genmab to Present at the Jefferies 2014 Global Healthcare Conference Nov 14 2014
    Report Pursuant to Section 28a of the Danish Securities Trading Act Nov 12 2014
    Capital Increase in Genmab as a Result of Employee Warrant Exercise Nov 12 2014
    Genmab's Financial Calendar for 2015 Nov 10 2014
    Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma Nov 10 2014
    Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology... Nov 06 2014
    Genmab Announces Financial Results for the First Nine Months of 2014 Nov 05 2014
    Genmab Announces Conditional Transfer of Ofatumumab Agreement Nov 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK